RE: RE: Six Month Report??Q4 is the target for the 12-month data from 2b. More important tho imo is the end of Phase 2 meeting with the FDA and Euro Zone reviewers and the issue of the IND (and its Euro Zone equivalent) as this will establish the parameters for Phase 3, set the preferred clinical/business strategies and hence PRX's funding needs and/or partner opportunities. Also important in this issue is the near term payment of $5 million from Keisei.
I wouldn't be surprised if we're left hanging until late Q4 on resolution these important events that will help clarify PRX's needs and greatly influence its stock price.